IceCure Medical Achieves Nasdaq Compliance
IceCure Medical Ltd. (NASDAQ: ICCM), a leading innovator in minimally-invasive cryoablation technology, has proudly announced that it has regained compliance with Nasdaq’s minimum bid price requirement. This significant development attests to the company’s resilience and growth potential in the market.
Regaining Compliance with Nasdaq
Recent notifications from Nasdaq Stock Market LLC confirmed IceCure's compliance with the minimum closing bid price set forth in Nasdaq Listing Rule 5550(a)(2). The evaluation by Nasdaq officials found that the company’s shares have maintained a minimum closing price of $1.00 or more for at least 10 consecutive business days ahead of the compliance notice.
Future Prospects for IceCure Medical
With full compliance achieved, IceCure is reaffirmed in its listing and trading position on The Nasdaq Capital Market. This accomplishment underscores the effective strategies IceCure has implemented and reflects a solid foundation for future growth. The company is poised to capitalize on its advanced cryoablation technology as it seeks to expand its reach and enhance treatments for patients with tumors.
Innovative Cryoablation Technology
IceCure Medical specializes in the development and distribution of advanced cryoablation therapy systems designed to treat various tumors, both benign and cancerous. The technology efficiently freezes tumors as a safe alternative to traditional surgical procedures, particularly targeting breast, kidney, bone, and lung cancers. The flagship ProSense® system stands at the forefront of this innovative approach, marketed globally, including in the U.S., Europe, and China.
Commitment to Research and Development
Investment in research and development remains a central pillar of IceCure’s strategy. By continually enhancing technology and treatment protocols, IceCure Medical aims to improve patient outcomes further and solidify its market leadership in minimally-invasive procedures. The advancements made by IceCure are crucial not only for its brand but also contribute positively to the healthcare community and improve the quality of care for patients.
Contact Information for Investors
For any inquiries regarding company developments, investors can reach out directly via email at investors@icecure-medical.com. Contact persons include Michael Polyviou, reachable at 732-232-6914, and Todd Kehrli at 310-625-4462.
Frequently Asked Questions
What does it mean for IceCure Medical to regain Nasdaq compliance?
Regaining compliance indicates that IceCure has met the minimum bid price requirements established by Nasdaq, ensuring its continued listing and trading on the exchange.
What technology does IceCure develop?
IceCure specializes in minimally-invasive cryoablation technology that destroys tumors by freezing, presenting a less invasive alternative to traditional surgical removal.
In which markets is IceCure's technology available?
IceCure’s technology is available in various markets, including the U.S., Europe, and China, enhancing access for patients in need of innovative cancer treatment.
How does IceCure Medical plan to grow?
The company aims to expand its product offerings and improve treatment protocols through ongoing research and development initiatives.
Who can investors contact for more information?
Investors seeking more information can contact IceCure via email or directly reach out to the investor relations team, including Michael Polyviou and Todd Kehrli.
